Patents by Inventor Pingyuan Wang

Pingyuan Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240059655
    Abstract: Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.
    Type: Application
    Filed: August 27, 2023
    Publication date: February 22, 2024
    Inventors: Jia ZHOU, John A. ALLEN, Pingyuan WANG, Daniel E. FELSING
  • Patent number: 11773065
    Abstract: Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: October 3, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jia Zhou, John A. Allen, Pingyuan Wang, Daniel E. Felsing
  • Publication number: 20230150929
    Abstract: The invention relates generally to novel EPAC1 activators, such as Formula I and II and the preparation thereof as well as the use of EPAC1 activators disclosed herein as to selectively activate EPAC1 in cells.
    Type: Application
    Filed: March 17, 2021
    Publication date: May 18, 2023
    Inventors: Jia Zhou, Stephen Yarwood, Pingyuan Wang, Urszula Luchowska-Stanska, Boy van Basten
  • Publication number: 20220177440
    Abstract: The invention relates generally to the following novel fendiline derivatives, and the preparation and use thereof: Formula I (I) and Formula II (II)
    Type: Application
    Filed: March 5, 2020
    Publication date: June 9, 2022
    Inventors: John F. Hancock, Jia Zhou, Dharnii van der Hoeven, Jeffrey A. Frost, Na Ye, Pingyuan Wang
  • Publication number: 20220112164
    Abstract: Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 14, 2022
    Inventors: Jia ZHOU, John A. ALLEN, Pingyuan WANG, Daniel E. FELSING
  • Publication number: 20210019725
    Abstract: A transaction record is created showing a purchase transaction of a customer. A CV profile showing a list of items in the transaction obtained from images is also obtained. The items in the transaction record are compared to items on the list. When there is a discrepancy, an action to take is determined.
    Type: Application
    Filed: July 16, 2020
    Publication date: January 21, 2021
    Inventors: Zhichun Xiao, Lingfeng Zhang, Jon Hammer, Joseph Duffy, Yao Liu, Sicong Fang, Xiang Yao, Pingyuan Wang, Yu Tao, Tianyi Mao, Yutao Tang, Feiyun Zhu, Han Zhang, Chunmei Wang, Pingjian Yu, Muzzammil Afroz, Haining Liu
  • Patent number: 10597399
    Abstract: A class of substituted triazolopiperazine compounds represented by formula (I), tautomers, enantiomers, diastereomers, racemates, metabolites, metabolic precursors, and pharmaceutically acceptable salts, esters, prodrugs or hydrate thereof, a preparation methods therefor, intermediates and a use thereof in the preparation of drugs for prevention and treatment of diseases associated with PARP including various ischemic diseases, neurodegenerative diseases and cancers.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: March 24, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Ao Zhang, Zehong Miao, Pingyuan Wang, Shanshan Song, Zilan Song, Xiajuan Huan, Zhoulong Fan, Jian Ding
  • Publication number: 20180265516
    Abstract: The present invention relates to a class of substituted triazolopiperazine compounds, tautomers, enantiomers, diastereomers, racemates, metabolites, metabolic precursors, and pharmaceutically acceptable salts, esters, prodrugs or hydrate thereof, a preparation methods therefor, intermediates and a use thereof in the preparation of drugs for prevention and treatment of diseases associated with PARP including various ischemic diseases, neurodegenerative diseases and cancers.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Ao Zhang, Zehong Miao, Pingyuan Wang, Shanshan Song, Zilan Song, Xiajuan Huan, Zhoulong Fan, Jian Ding